{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T02:32:34Z","timestamp":1791513154309,"version":"4.3.4"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2021,8,30]],"date-time":"2021-08-30T00:00:00Z","timestamp":1630281600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100009060","name":"SIDACTION","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003323","name":"ANRS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003323","id-type":"DOI","asserted-by":"publisher"}]},{"name":"French HIV-HBV"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,10,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To determine the extent of hepatitis B virus (HBV) suppression and its association with seroclearance of hepatitis \u2018e\u2019 antigen (HBeAg) and hepatitis B surface antigen (HBsAg) in HIV\/HBV-coinfected patients undergoing long-term tenofovir-based antiretroviral therapy (ART).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We prospectively followed 165 HIV\/HBV-coinfected patients undergoing tenofovir-based ART. Serum HBV-DNA viral loads and HBeAg and HBsAg status were obtained at tenofovir initiation and every 6\u201312\u2009months. We calculated the proportion achieving virological response (VR, &amp;lt;60\u2009IU\/mL) during follow-up. We also calculated rates of HBeAg- and HBsAg-seroclearance, which were compared between those who achieved versus never achieved VR during follow-up using an Exact binomial test.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>During a median 8.1\u2009years (IQR\u200a=\u200a4.0\u201313.2) of tenofovir treatment, 152 (92.1%) patients were able to achieve VR and 13 (7.9%) never achieved VR (median HBV-DNA at the end of follow-up\u200a=\u200a608\u2009IU\/mL, range\u200a=\u200a67\u201352\u200a400\u200a000). The prevalence of individuals with detectable HBV-DNA (\u226560\u2009IU\/mL) decreased during tenofovir treatment: 15.1% (n\u200a=\u200a14\/93) at 5\u2009years, 3.2% (n\u200a=\u200a2\/62) at 10\u2009years and, 3.2% (n\u200a=\u200a1\/31) at 15\u2009years. 44\/96 HBeAg-positive patients (6.15\/100 person-years) had HBeAg-seroclearance and 13\/165 patients overall (0.87\/100 person-years) had HBsAg-seroclearance. No difference in HBeAg-seroclearance was observed between those who achieved versus never achieved VR (7.4 versus 3.7\/100 person-years, P\u200a=\u200a0.33), while HBsAg-seroclearance was only observed in those with VR (1.0 versus 0\/100 person-years, P\u200a=\u200a0.49; respectively). Individuals with VR also had a higher frequency of undetectable HIV-RNA during treatment (P\u200a&amp;lt;\u200a0.001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>During long-term tenofovir-based ART for HIV\/HBV coinfection, persistent HBV viraemia is apparent, but becomes less frequent over time. HBsAg-seroclearance only occurred in those with full HBV and relatively high HIV suppression.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkab294","type":"journal-article","created":{"date-parts":[[2021,7,27]],"date-time":"2021-07-27T15:11:27Z","timestamp":1627398687000},"page":"3009-3019","source":"Crossref","is-referenced-by-count":12,"title":["Persistent HBV replication and serological response during up to 15 years of tenofovir-based antiretroviral therapy in HIV\/HBV-coinfected patients: a multicentre prospective cohort study"],"prefix":"10.1093","volume":"76","author":[{"given":"Lorenza N C","family":"Dezanet","sequence":"first","affiliation":[{"name":"Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis d'\u00c9pid\u00e9miologie et de Sant\u00e9 Publique, IPLESP, Paris F75012, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Miailhes","sequence":"additional","affiliation":[{"name":"H\u00f4pital de la Croix-Rousse, Hospices Civils de Lyon, Service de Maladies Infectieuses et Tropicales, Lyon F69317, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Lascoux-Combe","sequence":"additional","affiliation":[{"name":"APHP, H\u00f4pital Saint-Louis, Service de Maladies Infectieuses, Paris F75010, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Chas","sequence":"additional","affiliation":[{"name":"APHP, H\u00f4pital Tenon, Service de Maladies Infectieuses, Paris F75020, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Maylin","sequence":"additional","affiliation":[{"name":"APHP, H\u00f4pital Saint-Louis, Laboratoire de Virologie, Paris F75010, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Gabassi","sequence":"additional","affiliation":[{"name":"APHP, H\u00f4pital Saint-Louis, Laboratoire de Virologie, Paris F75010, France"},{"name":"Universit\u00e9 de Paris, INSERM U944, Institut de Recherche Saint-Louis, Paris F75010, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayette","family":"Rougier","sequence":"additional","affiliation":[{"name":"IMEA, Institut de M\u00e9decine et d\u2019Epid\u00e9miologie Appliqu\u00e9e, Paris F75018, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constance","family":"Delaugerre","sequence":"additional","affiliation":[{"name":"APHP, H\u00f4pital Saint-Louis, Laboratoire de Virologie, Paris F75010, France"},{"name":"Universit\u00e9 de Paris, INSERM U944, Institut de Recherche Saint-Louis, Paris F75010, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karine","family":"Lacombe","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis d'\u00c9pid\u00e9miologie et de Sant\u00e9 Publique, IPLESP, Paris F75012, France"},{"name":"APHP, H\u00f4pital Saint-Antoine, Service de Maladies Infectieuses et Tropicales, Paris F75012, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Boyd","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis d'\u00c9pid\u00e9miologie et de Sant\u00e9 Publique, IPLESP, Paris F75012, France"},{"name":"APHP, H\u00f4pital Saint-Antoine, Service de Maladies Infectieuses et Tropicales, Paris F75012, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,8,30]]},"reference":[{"key":"2021101808550638100_dkab294-B1","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1097\/QAD.0000000000000222","article-title":"Causes of death among HIV-infected patients in France in 2010 (national survey): trends since 2000","volume":"28","author":"Morlat","year":"2014","journal-title":"AIDS"},{"key":"2021101808550638100_dkab294-B2","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1089\/aid.2019.0143","article-title":"Mortality of people living with HIV in Paris area from 2011 to 2015","volume":"36","author":"Sellier","year":"2020","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2021101808550638100_dkab294-B3","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1097\/QAD.0b013e32833a0918","article-title":"Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study","volume":"24","author":"Smith","year":"2010","journal-title":"AIDS"},{"key":"2021101808550638100_dkab294-B4","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","year":"2017","journal-title":"J Hepatol"},{"key":"2021101808550638100_dkab294-B5"},{"key":"2021101808550638100_dkab294-B6","doi-asserted-by":"crossref","first-page":"e68152","DOI":"10.1371\/journal.pone.0068152","article-title":"Suppression of HBV by tenofovir in HBV\/HIV coinfected patients: a systematic review and meta-analysis","volume":"8","author":"Price","year":"2013","journal-title":"PLoS One"},{"key":"2021101808550638100_dkab294-B7","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/jvh.12613","article-title":"No detectable resistance to tenofovir disoproxil fumarate in HBeAg+ and HBeAg\u2212 patients with chronic hepatitis B after 8 years of treatment","volume":"24","author":"Liu","year":"2017","journal-title":"J Viral Hepat"},{"key":"2021101808550638100_dkab294-B8","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1002\/hep.27182","article-title":"Persistent viremia in human immunodeficiency virus\/hepatitis B coinfected patients undergoing long-term tenofovir: virological and clinical implications","volume":"60","author":"Boyd","year":"2014","journal-title":"Hepatology"},{"key":"2021101808550638100_dkab294-B9","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/jvh.12142","article-title":"Incidence and risk factors for incomplete HBV DNA suppression in HIV\/HBV-co-infected patients initiating tenofovir-based therapy","volume":"21","author":"Hafkin","year":"2014","journal-title":"J Viral Hepat"},{"key":"2021101808550638100_dkab294-B10","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1177\/2325957415586258","article-title":"Outcomes in HIV\/HBV-coinfected patients in the tenofovir era are greatly affected by immune suppression","volume":"14","author":"Huang","year":"2015","journal-title":"J Int Assoc Provid AIDS Care"},{"key":"2021101808550638100_dkab294-B11","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1097\/QAD.0000000000001080","article-title":"Effects of long-term tenofovir-based combination antiretroviral therapy in HIV-hepatitis B virus coinfection on persistent hepatitis B virus viremia and the role of hepatitis B virus quasispecies diversity","volume":"30","author":"Audsley","year":"2016","journal-title":"AIDS"},{"key":"2021101808550638100_dkab294-B12","doi-asserted-by":"crossref","first-page":"e87\u201394","DOI":"10.1093\/cid\/cit002","article-title":"Patterns and causes of suboptimal response to tenofovir-based therapy in individuals coinfected with HIV and hepatitis B virus","volume":"56","author":"Matthews","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2021101808550638100_dkab294-B13","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1053\/j.gastro.2010.08.045","article-title":"Long-term therapy with tenofovir is effective for patients co-infected with human immunodeficiency virus and hepatitis B virus","volume":"139","author":"de Vries\u2013Sluijs","year":"2010","journal-title":"Gastroenterology"},{"key":"2021101808550638100_dkab294-B14","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1111\/liv.14155","article-title":"Ten-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B virus infection","volume":"39","author":"Marcellin","year":"2019","journal-title":"Liver Int"},{"key":"2021101808550638100_dkab294-B15","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s12072-019-09953-4","article-title":"Long-term virological and serologic responses of chronic hepatitis B virus infection to tenofovir disoproxil fumarate-containing regimens in patients with HIV and hepatitis B coinfection","volume":"13","author":"Huang","year":"2019","journal-title":"Hepatol Int"},{"key":"2021101808550638100_dkab294-B16","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1111\/jgh.13156","article-title":"Hepatitis B surface antigen quantification as a predictor of seroclearance during treatment in HIV-hepatitis B virus coinfected patients from Sub-Saharan Africa: Seroclearance during treatment","volume":"31","author":"Boyd","year":"2016","journal-title":"J Gastroenterol Hepatol"},{"key":"2021101808550638100_dkab294-B17","doi-asserted-by":"crossref","first-page":"e24731","DOI":"10.2196\/24731","article-title":"Subclinical and clinical outcomes in patients coinfected with HIV and chronic hepatitis B virus from clinical outpatient centers in France: protocol for an ambispective, longitudinal cohort study","volume":"10","author":"Boyd","year":"2021","journal-title":"JMIR Res Protoc"},{"key":"2021101808550638100_dkab294-B18","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1097\/QAD.0000000000000795","article-title":"Rates and determinants of hepatitis B \u2018e\u2019 antigen and hepatitis B surface antigen seroclearance during long-term follow-up of patients coinfected with HIV and hepatitis B virus","volume":"29","author":"Boyd","year":"2015","journal-title":"AIDS"},{"key":"2021101808550638100_dkab294-B19","doi-asserted-by":"crossref","first-page":"3072","DOI":"10.1007\/s10620-015-4027-8","article-title":"Effectiveness and safety of tenofovir disoproxil fumarate in chronic hepatitis B: a 3-year, prospective, real-world study in France","volume":"61","author":"Marcellin","year":"2016","journal-title":"Dig Dis Sci"},{"key":"2021101808550638100_dkab294-B20","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1002\/hep.26374","article-title":"High incidence of treatment-induced and vaccine-escape hepatitis B virus mutants among human immunodeficiency virus\/hepatitis B-infected patients","volume":"58","author":"Lacombe","year":"2013","journal-title":"Hepatology"},{"key":"2021101808550638100_dkab294-B21","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s11901-011-0096-0","article-title":"Noninvasive markers of hepatic fibrosis in chronic hepatitis B","volume":"10","author":"Poynard","year":"2011","journal-title":"Curr Hepat Rep"},{"key":"2021101808550638100_dkab294-B22","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.jhep.2009.01.022","article-title":"Performance of 11 biomarkers for liver fibrosis assessment in HIV\/HBV co-infected patients","volume":"50","author":"Bottero","year":"2009","journal-title":"J Hepatol"},{"key":"2021101808550638100_dkab294-B23","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1002\/hep.26277","article-title":"Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load","volume":"58","author":"Gordon","year":"2013","journal-title":"Hepatology"},{"key":"2021101808550638100_dkab294-B24","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1128\/JVI.79.5.3038-3051.2005","article-title":"Reduced hepatitis B virus (HBV)-specific CD4+ T-cell responses in human immunodeficiency virus type 1-HBV-coinfected individuals receiving HBV-active antiretroviral therapy","volume":"79","author":"Chang","year":"2005","journal-title":"J Virol"},{"key":"2021101808550638100_dkab294-B25","doi-asserted-by":"crossref","first-page":"7649","DOI":"10.1128\/JVI.00183-09","article-title":"Impaired quality of the hepatitis B virus (HBV)-specific T-cell response in human immunodeficiency virus type 1-HBV coinfection","volume":"83","author":"Chang","year":"2009","journal-title":"J Virol"},{"key":"2021101808550638100_dkab294-B26","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/QAD.0b013e3283410ccb","article-title":"Increased intrahepatic apoptosis but reduced immune activation in HIV-HBV co-infected patients with advanced immunosuppression","volume":"25","author":"Iser","year":"2011","journal-title":"AIDS"},{"key":"2021101808550638100_dkab294-B27"},{"key":"2021101808550638100_dkab294-B28","doi-asserted-by":"crossref","first-page":"S112","DOI":"10.1016\/S0168-8278(12)60012-9","article-title":"Management of treatment failure in chronic hepatitis B","volume":"56","author":"Zoulim","year":"2012","journal-title":"J Hepatol"},{"key":"2021101808550638100_dkab294-B29","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1002\/hep.28461","article-title":"Novel quantification of tenofovir disoproxil fumarate adherence in human immunodeficiency virus\/hepatitis B coinfected patients with incomplete hepatitis B virus viral suppression","volume":"64","author":"Wong","year":"2016","journal-title":"Hepatology"},{"key":"2021101808550638100_dkab294-B30","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1742-6405-9-6","article-title":"Assessment of HBV flare in a randomized clinical trial in HIV\/HBV coinfected subjects initiating HBV-active antiretroviral therapy in Thailand","volume":"9","author":"Avihingsanon","year":"2012","journal-title":"AIDS Res Ther"},{"key":"2021101808550638100_dkab294-B31","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1053\/gast.2001.22461","article-title":"Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease","volume":"120","author":"Perrillo","year":"2001","journal-title":"Gastroenterology"},{"key":"2021101808550638100_dkab294-B32","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/j.1440-1746.2011.06695.x","article-title":"Natural history of chronic hepatitis B REVEALed","volume":"26","author":"Chen","year":"2011","journal-title":"J Gastroenterol Hepatol"},{"key":"2021101808550638100_dkab294-B33","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s12072-015-9614-4","article-title":"Long-term clinical outcomes in cirrhotic chronic hepatitis B patients treated with tenofovir disoproxil fumarate for up to 5 years","volume":"9","author":"Buti","year":"2015","journal-title":"Hepatol Int"},{"key":"2021101808550638100_dkab294-B34","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.jhep.2019.02.006","article-title":"Identification of a quadruple mutation that confers tenofovir resistance in chronic hepatitis B patients","volume":"70","author":"Park","year":"2019","journal-title":"J Hepatol"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/76\/11\/3009\/40641675\/dkab294.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/76\/11\/3009\/40641675\/dkab294.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,20]],"date-time":"2021-10-20T16:24:51Z","timestamp":1634747091000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/76\/11\/3009\/6359434"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,30]]},"references-count":34,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,8,30]]},"published-print":{"date-parts":[[2021,10,11]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkab294","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.07.01.21259560","asserted-by":"object"}]},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,11,1]]},"published":{"date-parts":[[2021,8,30]]}}}